Bioqube Ventures’ Post

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/e5SBSaE4

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/gjRpuVH7

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/esz5bbfB

Keep your eye on biotech.... Pre-Commercial Biotech stocks are starting to gain favor. If you're thinking about diversifying.. Check out what our friends at AlphaWatch have to say about it. https://lnkd.in/eihzXBcN #investing #pharma #investinginbiotech #wealthmanagement #financialadvisors

After a year of significant volatility, biopharmaceutical leaders are divided on the causes that negatively affected the SPDR S&P Biotech ETF (XBI) and the NASDAQ Biotechnology Index (NBI) valuations. Some point to macroeconomic challenges as the clear drivers, while others cite an oversaturation of public companies or a lack of positive news flow. Uncover more findings and insights in Lazard’s 2024 Global Biopharmaceutical Leaders Study: https://lnkd.in/eDYDqhnY

Biopharma M&A more than doubled in the first quarter compared to the year prior: report https://lnkd.in/dNJ_DQB2 The number of biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and [...]

Biotech initial public offerings (IPOs) are essential for funding emerging drugmakers, but recent market fluctuations have made the landscape more challenging. Stay informed with this regularly updated database that tracks IPO activity, company performance, and investment trends in the biotechnology sector from BioPharma Dive: https://lnkd.in/evy-5Kps

Opyl has partnered with L39 Capital Pty Ltd to launch an AI Biotech Fund. This fund will leverage our proprietary TrialKey technology, targeting $100M in AUM within 36 months. TrialKey’s predictive power will help us identify high-return biotech stocks, initially focusing on the US and Australia with over 200 annual inflection points. Book a demo:https://lnkd.in/grvHkpXN Marketing and investor enquiries: bernice.averion@opyl.ai  #aiinbiotech #clinicaltrials #opyl #investment #biotech #biopharma #medtech #pharmaceuticals #healthcare #softwaredevelopment #asx #investing"

55 novel drugs were approved in 2023, almost a 50% increase from 2022 (37 approved). The biotech IPO market has also seen a sharp decline in the last 2 years compared to 2021, with only 18 IPOs in each 2022 and 2023, compared with 108 in 2022. We are hoping that the number of drugs approved this past year combined with improving economic conditions (mainly, interest rate stabilization) will cultivate growth in the industry in 2024. #biotech #biotechinvesting #macro #biotechstocks https://lnkd.in/eh8NC-66

Calidi Biotherapeutics, a biotech company developing targeted immunotherapies, has successfully priced its public offering for 15,197,500 shares of common stock or pre-funded warrants. The offering also includes Series A, B, and C Common Warrants, each comprising one share of common stock and a corresponding warrant, with a combined effective price of $0.40, generating approximately $6.1 million in gross proceeds. Ladenburg Thalmann & Co. Inc. is the sole placement agent for the offering. The proceeds from the offering will primarily be used for working capital, general corporate purposes, and pre-clinical and clinical trials. The common warrants have an exercise price of $0.60 per share and will expire at various intervals from the issuance date. The offering is made through a registration statement filed with the Securities and Exchange Commission (SEC) and became effective on April 15, 2024. Both preliminary and final prospectuses are available on the SEC's website. #CalidiBiotherapeutics #Immunotherapy #Biotech #StockOffering #SEC #LadenburgThalmann Steve Thesing